← Back to Search

Rehabilitation for Cancer Survivors (HIMALAYAS Trial)

N/A
Recruiting
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Received cancer treatment(s) with known cardiovascular risks (e.g. anthracyclines, radiotherapy, trastuzumab, platinum-based agents, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors) in the previous 5 years;
Be an AYA-CS, defined as ≤39 years of age at the time of cancer diagnosis;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study initiation to end of 66-month study period (primary and secondary rcts)
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to study the effectiveness of a Cardio-Oncology Rehabilitation (CORE) program on the cardiovascular and psychosocial health of pediatric, adolescent, and young adult cancer survivors (PAYA-CS

Who is the study for?
This trial is for young cancer survivors under 39 diagnosed at the time of their cancer, now aged 18 or older. They must have had treatments with cardiovascular risks within the last 5 years and be free of cancer at enrollment. Participants should have mild heart dysfunction but cannot join if they don't meet specific heart health criteria.
What is being tested?
The HIMALAYAS study tests a Cardio-Oncology Rehabilitation (CORE) program against standard care in young adult cancer survivors with mild heart issues. CORE includes exercise, behavioral support, and managing heart disease risk factors over six months to improve fitness and psychosocial health.
What are the potential side effects?
While not explicitly stated, potential side effects may include muscle soreness, fatigue from exercise programs in CORE intervention; however, these are generally well-tolerated and beneficial for long-term cardiovascular health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I've had cancer treatments that could affect my heart in the last 5 years.
Select...
I was diagnosed with cancer at or before the age of 39.
Select...
I have been diagnosed with a specific heart condition affecting its function and structure.
Select...
I am 18 years old or older.
Select...
I am currently cancer-free.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study initiation to end of 66-month study period (primary and secondary rcts)
This trial's timeline: 3 weeks for screening, Varies for treatment, and study initiation to end of 66-month study period (primary and secondary rcts) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cardiorespiratory fitness
Secondary study objectives
Anaerobic threshold
Anxiety
Apolipoprotein B
+27 more
Other study objectives
Behavioural Compliance
Energy expenditure during HIIT
Exercise Adherence
+13 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Cardio-Oncology Rehabilitation (CORE)Experimental Treatment1 Intervention
Participants in the CORE group will have 1. A personalized, supervised exercise program ((in-person at intuition and virtual/ homebased exercises) 2. CV risk factor management, 3. behavioural support for the first 6 months. The behavioural support will continue for CORE participants from months 7-24. Behavioural support includes professionally guided and peer-enhanced exercise behavioural support based on behaviour change stage theories. CORE participants will be provided a wrist-worn heart and physical activity monitor to use throughout the 24-month observation period.
Group II: Standard of Care (CON)Active Control1 Intervention
Participants in the CON group will receive standard medical care and physical activity will be monitored by a wrist-worn activity tracker for 2 years.

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,531 Previous Clinical Trials
503,986 Total Patients Enrolled
5 Trials studying Cardiotoxicity
659 Patients Enrolled for Cardiotoxicity
Centre hospitalier de l'Université de Montréal (CHUM)OTHER
378 Previous Clinical Trials
131,215 Total Patients Enrolled
Queen Elizabeth II Health Sciences CentreOTHER
25 Previous Clinical Trials
13,879 Total Patients Enrolled
Alberta Health servicesOTHER
163 Previous Clinical Trials
652,322 Total Patients Enrolled
Vancouver General HospitalOTHER
41 Previous Clinical Trials
19,339 Total Patients Enrolled
Université de MontréalOTHER
221 Previous Clinical Trials
103,859 Total Patients Enrolled
Dalhousie UniversityOTHER
173 Previous Clinical Trials
401,518 Total Patients Enrolled
University of AlbertaOTHER
942 Previous Clinical Trials
434,073 Total Patients Enrolled
2 Trials studying Cardiotoxicity
395 Patients Enrolled for Cardiotoxicity
University of British ColumbiaOTHER
1,481 Previous Clinical Trials
2,494,580 Total Patients Enrolled
University of TorontoOTHER
723 Previous Clinical Trials
1,115,252 Total Patients Enrolled
1 Trials studying Cardiotoxicity
180 Patients Enrolled for Cardiotoxicity
~210 spots leftby Sep 2026